CD44 Antibody Kit, anti-human, FITC, REAlease® from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for CD44 Antibody Kit, anti-human, FITC, REAlease® products.
| Edit | |
|---|---|
| Product Name | CD44 Antibody Kit, anti-human, FITC, REAlease® |
| Description | CD44 Antibody Kit, anti-human, FITC, REAlease®. Clone REAL259 is an antibody fragment derived from the full CD44 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity. | Clone REAL259 recognizes the CD44 antigen. CD44 is a marker for many types of cancer stem cells (CSC), including breast CSCs that possess higher tumorigenicity and metastatic potential, colorectal, pancreatic, and prostate CSCs. In addition, expression was observed in several cancers as well as on carcinoma cell lines. Here, CD44 plays a role in cancer cell migration and matrix adhesion in response to a cellular microenvironment, thus enhancing cellular aggregation and tumor cell growth. CD44 is also expressed on mesodermal cells, such as hematopoietic, fibroblastic, and glial cells. | The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes. |
| Size | 100 tests |
| Concentration | 1:50 |
| Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
| Other Names | CD44s, EMCR III, H-CAM, Pgp-1 |
| Gene, Accession, CAS # | n/a |
| Catalog # | 130-124-856 |
| Price | $385 |
| Order / More Info | CD44 Antibody Kit, anti-human, FITC, REAlease® from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Aruffo, A. et al. (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313. | Al-Hajj, M. et al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100: 3983-3988. | Collins, A. T. et al. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65: 10946-10951. | Patrawala, L. et al. (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696-1708. | Dalerba, P. et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U.S.A. 104: 10158-10163. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG